Safety and Immunogenicity of Inactivated Fowl Adenovirus Serotype 8b Isolate Following Different Inactivation Time Intervals in Broiler Chickens

Document Type : Original Articles

Authors

1 Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia.

2 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia

3 Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia

4 Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia

10.32592/ARI.2024.79.5.997

Abstract

In recent years, much attention has been focused on the development of inactivated fowl aviadenovirus (FAdV) vaccines in the poultry industry against inclusion body hepatitis (IBH) outbreak. It was the objective of this study to determine the safety and immunogenicity of inactivated FAdV vaccine following different inactivation time intervals in commercial broiler chickens. FAdV isolate, UPM1137 was treated with binary ethyleneimine (BEI) at 20 hours (h), 24h, 28h, 32h and 36h. All treated isolates were furthered tested for safety test in specific pathogen free (SPF) chicken embryonated eggs (CEE) followed by safety and immunogenicity trial in SPF chickens. Based on the current findings, it was demonstrated that the isolate treated at 20h, 24h and 28h induce more than 80% mortality in SPF CEE, while, no mortality was recorded for isolate treated at 32h and 36h. In SPF chickens, neither clinical signs, nor gross and histological lesions were recorded throughout the trial after inoculated with isolate treated at 32h and 36h. The isolate treated at 32h and 36h are completely inactivated and safe in commercial broiler chicken. Based on ELISA findings, chickens vaccinated with inactivated FAdV at 32 hours (h) (group B) induce high antibody response compared to that inactivated FAdV at 36h (group A) at day 14 and 28pi. At day 28pi, mean antibody titer for booster groups in group A and B were significantly high (p < 0.05) compared to the control group. It showed that both FAdV vaccine using inactivated inoculum at 32h and 36h are safe and immunogenic in broiler chickens typically at day 28pi following booster vaccination. It was concluded that the optimal period of FAdV inactivation was 32 hours and highly suitable to be used for future vaccine formulation.

Keywords

Main Subjects


  1. Harrach B, Benkő M, Both GW, Brown M, Davison AJ, Echavarría M,et al. Family adenoviridae. In: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ, editors., Virus taxonomy: classification and nomenclature of viruses. Ninth report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press. 2012. p 125-141.
  2. Cizmecigil UY, Umar S, Yilmaz A, Bayraktar E, Turan N, Tali B, et al. Characterisation of fowl adenovirus (FAdV-8b) strain concerning the geographic analysis and pathological lesions associated with inclusion body hepatitis in broiler flocks in Turkey. J Vet Res. 2020;64(2):231–7.
  3. Cui J, Xu Y, Zhou Z, Xu Q, Wang J, Xiao Y, et al. Pathogenicity and Molecular Typing of Fowl Adenovirus-Associated with hepatitis/hydropericardium syndrome in Central China (2015-2018). Front Vet Sci. 2020;7:190.
  4. Abghour S, Zro K, Mouahid M, Tahiri F, Tarta M, Berrada J, et al. Isolation and characterization of fowl aviadenovirus serotype 11 from chickens with inclusion body hepatitis in Morocco. PLoS ONE. 2019;14(12):e0227004.
  5. Schachner A, Matos M, Grafl B, Hess, M. Fowl adenovirus-induced diseases and strategies for their control - a review on the current global situation. Avian Pathol: Journal of the W.V.P.A. 2018;47(2):111–126.
  6. Sohaimi NM, Bejo MH, Omar AR, Ideris A, Mat Isa N. Molecular characterization of fowl adenovirus isolate of Malaysia attenuated in chicken embryo liver cells and its pathogenicity and immunogenicity in chickens. PLoS ONE. 2019;14(12): e0225863.
  7. Elveborg S, Monteil VM, Mirazimi A. Methods of inactivation of highly pathogenic viruses for molecular, serology or vaccine development purposes. Pathogens. 2022 Feb 19;11(2):271. doi: 10.3390/pathogens11020271.
  8. Ugwu CC, Hair-Bejo M, Nurulfiza MI, Omar AR, Ideris A. Efficacy, humoral, and cell-mediated immune response of inactivated fowl adenovirus 8b propagated in chicken embryo liver cells using bioreactor in broiler chickens. Vet World. 2022 Nov;15(11):2681-2692.
  9. Motamed N. An overview of future development methods of infectious bronchitis vaccines. Iranian J Vet Med. 2024;18(1):1-12.
  10. Pan Q, Yang Y, Gao Y, Qi X, Liu C, Zhang Y, et al. An inactivated novel genotype fowl adenovirus 4 protects chickens against the hydropericardium syndrome that recently emerged in China. Viruses. 2017;9(8):216.
  11. Gupta A, Popowich S, Ojkic D, Kurukulasuriya S, Chow-Lockerbie B, Gunawardana T, et al. Inactivated and live bivalent fowl adenovirus (FAdV8b + FAdV11) breeder vaccines provide broad-spectrum protection in chicks against inclusion body hepatitis (IBH). Vaccine. 2018;36(5):744–750.
  12. Junnu S, Lertwatcharasarakul P, Jala S, Phattanakulanan S, Monkong A, Kulprasertsri S, et al. An inactivated vaccine for prevention and control of inclusion body hepatitis in broiler breeders. Thai J Vet Med. 2015;45(1):55–62.
  13. Lone NA, Spackman E, Kapczynski D. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus. Vaccine. 2017;35(26):3401–3408.
  14. Mansoor MK, Hussain I, Arshad M, Muhammad G. Preparation and evaluation of chicken embryo-adapted fowl adenovirus serotype 4 vaccine in broiler chickens. Trop Anim Health Prod. 2011;43(2):331–338.
  15. Siddharta, A. Meat consumption per capita in Malaysia in 2023, by type. Statista Research Development. 2024.
  16. Habib M, Hussain I, Irshad H, Yang ZZ, Shuai JB, Chen N. Immunogenicity of formaldehyde and binary ethylenimine inactivated infectious bursal disease virus in broiler chicks. J Zhejiang Univ Sci B. 2006;7(8):660-4.
  17. Field A. Discovering statistics using IBM SPSS Statistics: And Sex and Drugs and Rock “N” Roll. 4th ed. SAGE Publications Ltd. 2013.
  18. Hess M. Detection and differentiation of avian adenoviruses: A review. Avian Pathol. 2000;29:195–206.
  19. Sarachai C, Sasipreeyajan, J, Chansiripornchai, N. Avian influenza virus (H5N1) inactivation by binary ethylenimine. Thai J Vet Med. 2010;40:1-4.
  20. Delrue I, Verzele D, Madder A, Nauwynck HJ. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines. 2012;11(6):695–719.
  21. Kim MS, Lim TH, Lee DH, Youn HN, Yuk SS, Kim BY, et al. An inactivated oil-emulsion fowl Adenovirus serotype 4 vaccine provides broad cross-protection against various serotypes of fowl Adenovirus. Vaccine. 2014;32(28):3564-8.
  22. Brown F, Meyer RF, Law M, Kramer E, Newman JFE. A universal virus inactivant for decontaminating blood and biopharmaceutical products. Biologicals. 1998;26(1):39-47.
  23. Maclachlan NJ, Dubovi EJ. Fenner`s veterinary virology, 5th ed. San Diego: Academic Press. 2017.
  24. Eladawy S, El-Bagoury G, El-Habbaa A, El-Mahdy S. Evaluation of formaldehyde and binary ethylenimine inactivated Newcastle disease virus vaccine from new isolate compared with imported NDV vaccine. Benha Vet Med J. 2020;38(2):34-40.
  25. De Luca C, Schachner A, Mitra T, Heidl S, Liebhart D, Hess M. Fowl adenovirus (FAdV) fiber-based vaccine against inclusion body hepatitis (IBH) provides type-specific protection guided by humoral immunity and regulation of B and T cell response. Vet Res, 2020;51(1):143.
  26. De Luca C, Schachner A, Heidl S, Hess M. Vaccination with a fowl adenovirus chimeric fiber protein (crecFib-4/11) simultaneously protects chickens against hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH). Vaccine. 2020;40(12):1837–1845.